TY - JOUR
T1 - MCT8 Deficiency in Females
AU - Groeneweg, Stefan
AU - Van Geest, Ferdy S.
AU - Van Der Most, Floor
AU - Abela, Lucia
AU - Alfieri, Paolo
AU - Bauer, Andrew J.
AU - Bertini, Enrico
AU - Cappa, Marco
AU - Çelik, Nurullah
AU - De Coo, Irenaeus F.M.
AU - Dolcetta-Capuzzo, Anna
AU - Dubinski, Ilja
AU - Granadillo, Jorge L.
AU - Hoefsloot, Lies H.
AU - Kalscheuer, Vera M.
AU - Van Der Knoop, Marieke M.
AU - Krude, Heiko
AU - McNerney, Kyle P.
AU - Paone, Laura
AU - Peeters, Robin P.
AU - Peters, Catherine
AU - Schuelke, Markus
AU - Schweizer, Ulrich
AU - Sprague, Jennifer E.
AU - Van Trotsenburg, A. S.Paul
AU - Wilpert, Nina Maria
AU - Zanni, Ginevra
AU - Van Zutven, Laura J.C.M.
AU - Visser, W. Edward
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society.
PY - 2026/1/1
Y1 - 2026/1/1
N2 - Context Monocarboxylate transporter (MCT) 8 facilitates thyroid hormone (TH) transport across the blood-brain barrier. Pathogenic variants in SLC16A2 cause MCT8 deficiency (Allan-Herndon-Dudley syndrome), characterized by intellectual and motor disability and abnormal thyroid function tests. MCT8 deficiency typically affects males due to its X-linked inheritance. Objective Here, we report 8 female patients with heterozygous pathogenic variants in SLC16A2 who presented with variable neurocognitive impairment, behavioral problems, and TH function abnormalities. Methods We performed X-chromosome inactivation studies in female patients in whom heterozygous pathogenic variants in SLC16A2 were identified. The effect of SLC16A2 variants on TH transport was assessed in transfected cells and patient-derived fibroblasts. Results In all patients (mean age 8.6 years; range, 2.3-25 years) routine care genetic analyses identified heterozygous variants in SLC16A2 (p.(R445C), p.(N193I), p.(G276R), t(X;20), resulting in a breakpoint in intron 1, t(X;19), resulting in a breakpoint in SLC16A2, p.(I562Sfs566∗), p.(G221R)). All missense variants showed substantially reduced MCT8-mediated TH uptake in transiently transfected cells. X-chromosome inactivation studies in patient cells showed skewed X-inactivation in all 7 evaluated individuals. In 5 out of 7 evaluated cases, MCT8-mediated 3,5,3′-triiodothyronine (T3) uptake in patient-derived fibroblasts was impaired to a similar degree as in fibroblasts derived from male patients with MCT8 deficiency. Conclusion Female patients with heterozygous pathogenic variants in SLC16A2 and skewed X-chromosome inactivation may present with variable neuro(psycho)logical, behavioral, and thyroid function test abnormalities. Female patients presenting with neurocognitive impairment and abnormal TH function tests (low free thyroxine and/or high total T3 concentrations) should be tested for genetic variants in SLC16A2.
AB - Context Monocarboxylate transporter (MCT) 8 facilitates thyroid hormone (TH) transport across the blood-brain barrier. Pathogenic variants in SLC16A2 cause MCT8 deficiency (Allan-Herndon-Dudley syndrome), characterized by intellectual and motor disability and abnormal thyroid function tests. MCT8 deficiency typically affects males due to its X-linked inheritance. Objective Here, we report 8 female patients with heterozygous pathogenic variants in SLC16A2 who presented with variable neurocognitive impairment, behavioral problems, and TH function abnormalities. Methods We performed X-chromosome inactivation studies in female patients in whom heterozygous pathogenic variants in SLC16A2 were identified. The effect of SLC16A2 variants on TH transport was assessed in transfected cells and patient-derived fibroblasts. Results In all patients (mean age 8.6 years; range, 2.3-25 years) routine care genetic analyses identified heterozygous variants in SLC16A2 (p.(R445C), p.(N193I), p.(G276R), t(X;20), resulting in a breakpoint in intron 1, t(X;19), resulting in a breakpoint in SLC16A2, p.(I562Sfs566∗), p.(G221R)). All missense variants showed substantially reduced MCT8-mediated TH uptake in transiently transfected cells. X-chromosome inactivation studies in patient cells showed skewed X-inactivation in all 7 evaluated individuals. In 5 out of 7 evaluated cases, MCT8-mediated 3,5,3′-triiodothyronine (T3) uptake in patient-derived fibroblasts was impaired to a similar degree as in fibroblasts derived from male patients with MCT8 deficiency. Conclusion Female patients with heterozygous pathogenic variants in SLC16A2 and skewed X-chromosome inactivation may present with variable neuro(psycho)logical, behavioral, and thyroid function test abnormalities. Female patients presenting with neurocognitive impairment and abnormal TH function tests (low free thyroxine and/or high total T3 concentrations) should be tested for genetic variants in SLC16A2.
KW - MCT8
KW - monocarboxylate transporter 8
KW - neurocognitive impairment
KW - skewed X-chromosome inactivation
KW - thyroid hormone
KW - thyroid hormone transport
UR - https://www.scopus.com/pages/publications/105025125376
U2 - 10.1210/clinem/dgaf311
DO - 10.1210/clinem/dgaf311
M3 - Article
C2 - 40420837
AN - SCOPUS:105025125376
SN - 0021-972X
VL - 111
SP - e175-e184
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -